China Rogier Janssens, GM of the Biopharma business of Merck KGaA, Darmstadt, Germany in China, shares the highlights of his first 16 months at the affiliate; the impact of the regulatory changes on the Biopharma business of Merck KGaA, Darmstadt, Germany in China; the significance of the affiliate’s commercial growth as…
Opinion Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In this article, he gives his predictions for the political landscape in healthcare for 2019. The challenges for firms are painfully apparent—there is bipartisan support in the US to lower drug prices, a pervasive sense that traditional advocacy methods are failing in today’s political climate,…
China Kang Wei, managing director for the R&D-based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment, shares her priorities for RDPAC in the next few years, her members’ contribution to the Chinese healthcare environment and the national Healthy China 2030 strategy, as well as the importance…
China Steven Lynch, managing director of the British Chamber of Commerce in China, introduces the Chamber’s activities in support of their members, the research they are undertaking to produce a position paper on UK PLC in China in 2019 and the great opportunities for British businesses in China. Brexit does…
China Song Ruilin, executive president of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), discusses his association’s mandate, key achievements and the future of innovative Chinese pharmaceuticals and biotech. Innovation is at the core of PhIRDA. Any organization that supports innovation, realizes the country’s dream of biomedical innovation and…
China Following China’s vaccine scandal earlier this year, the country’s drug administration has considerably tightened up inspection processes of vaccine manufacturers which is causing shortages and raising the risk of widespread flu infection. In July this year, Chinese vaccine producer Changsheng Biotechnology (who account for 15 percent of China’s flu…
China China’s stupendous economic resurgence over the past four decades never ceases to awe, but what has captured attention in recent years has been the country’s international awakening. Against a nasty backdrop of intensifying populist nationalism, right-wing radicalism and trade protectionism in many advanced economies, Chinese President Xi Jinping’s surprising 2017…
China Cash has always ruled the start-up world and when it comes to the healthcare and life sciences sphere, the heavy investment required for R&D and the long timelines make it even more so. Luckily, China is now the second-largest VC market in the world, and a recent Preqin report highlighted that USD 65…
China The Greater Bay Area’s – and in particular, Shenzhen’s – prowess in life sciences manufacturing and development must also be attributed to the decades of experience and expertise gained from acting as OEM/ODM to global companies, in line with China’s overall positioning as the world’s factory floor. One of the…
Hong Kong Energetically touting itself as “Asia’s World City” as well as a connector between East and West with its inextricable links to both mainland China and the international community, Hong Kong is today seeking to augment her position as a global financial center by transforming herself into a biotech and biomedical…
Korea Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu assesses the changing environment for clinical research in Korea and offers her view on the successes and scope for improvement…
China The Honorable William Zarit, Chairman of the American Chamber of Commerce in Beijing (AmCham Beijing), shares the insights gained over his 25 years in China, the key priorities of AmCham Beijing regarding trade and economic linkages, and the fundamental need for both countries to strike a new ‘grand bargain’ based…
See our Cookie Privacy Policy Here